Repifermin

Repifermin is a recombinant human growth factor known as keratinocyte growth factor-2 (KGF-2). It is a member of the fibroblast growth factor (FGF) family, specifically FGF-10, and is involved in the proliferation and differentiation of epithelial cells. Repifermin has been studied for its potential therapeutic applications in wound healing, mucositis, and other conditions involving epithelial damage.

Mechanism of Action

Repifermin functions by binding to the fibroblast growth factor receptor 2b (FGFR2b), which is predominantly expressed in epithelial tissues. Upon binding, it activates intracellular signaling pathways that lead to the proliferation and migration of epithelial cells. This activity is crucial for the repair and regeneration of damaged epithelial tissues, making repifermin a candidate for treating conditions such as oral mucositis, ulcerative colitis, and chronic wounds.

Clinical Applications

Repifermin has been investigated in several clinical trials for its efficacy in treating various conditions:

• Oral Mucositis: Repifermin has been studied for its ability to reduce the severity and duration of oral mucositis in patients undergoing chemotherapy or radiation therapy. By promoting epithelial cell growth, it helps in the rapid healing of the mucosal lining.

• Wound Healing: In chronic wound conditions, such as diabetic foot ulcers, repifermin has shown potential in accelerating wound closure and improving healing outcomes.

• Gastrointestinal Disorders: The growth factor has been explored for its role in treating inflammatory bowel diseases like ulcerative colitis, where it may help in repairing the intestinal epithelium.

Research and Development

Repifermin was initially developed by Human Genome Sciences and has undergone various phases of clinical trials. However, its development has faced challenges, including mixed results in efficacy and safety profiles, leading to a pause in its advancement for certain indications.

Safety and Side Effects

The safety profile of repifermin has been evaluated in clinical trials. Common side effects include mild to moderate injection site reactions, headache, and gastrointestinal disturbances. Long-term safety data is limited, and further studies are needed to fully understand the risk-benefit ratio of repifermin therapy.

Also see

• Fibroblast growth factor
• Keratinocyte growth factor
• Epithelial tissue
• Wound healing
• Oral mucositis